Therapy News and Research

RSS
Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Researchers develop new high-tech device for transferring DNA into cells

Researchers develop new high-tech device for transferring DNA into cells

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

Intensive insulin treatment improves survival for diabetic heart attack patients

Intensive insulin treatment improves survival for diabetic heart attack patients

Minimally invasive TAVR procedure saves more lives than open-heart surgery, shows study

Minimally invasive TAVR procedure saves more lives than open-heart surgery, shows study

CNS stimulant no more effective than placebo for alleviating lung cancer fatigue

CNS stimulant no more effective than placebo for alleviating lung cancer fatigue

Scientists find new drug that improves effectiveness of radiotherapy in stopping tumor growth

Scientists find new drug that improves effectiveness of radiotherapy in stopping tumor growth

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Johns Hopkins scientists identify genetic marker associated with development of obsessive-compulsive disorder

Johns Hopkins scientists identify genetic marker associated with development of obsessive-compulsive disorder

Researchers identify target molecules for development of new allergy drugs

Researchers identify target molecules for development of new allergy drugs

Study reveals 70% of patients with diabetic retinopathy will develop macular edema

Study reveals 70% of patients with diabetic retinopathy will develop macular edema

University of Chicago receives $3.9M award to serve as Lead Academic Participating Site for NCTN

University of Chicago receives $3.9M award to serve as Lead Academic Participating Site for NCTN

Researchers use molecular diagnostic methods to detect cancer

Researchers use molecular diagnostic methods to detect cancer

Researchers identify several target molecules suitable for development of new allergy drugs

Researchers identify several target molecules suitable for development of new allergy drugs

Treating older men with early-stage prostate cancer does not help live longer

Treating older men with early-stage prostate cancer does not help live longer

2 genes work together to drive most lethal forms of prostate cancer

2 genes work together to drive most lethal forms of prostate cancer

Abeona Therapeutics obtains FDA Orphan Drug Designations for Sanfilippo Syndrome therapies

Abeona Therapeutics obtains FDA Orphan Drug Designations for Sanfilippo Syndrome therapies

Esaote gets FDA clearance to market Virtual Navigator fusion imaging technology for ultrasound

Esaote gets FDA clearance to market Virtual Navigator fusion imaging technology for ultrasound

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.